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Background. A subgroup of human immunodeficiency virus type 1 (HIV-1)–infected patients with 
severe immunodeficiency show persistently low CD4+ cell counts despite sustained viral suppression. 
It is unclear whether this immuno-virological discordance translates into an increased risk for clinical 
events.  
Methods. Data analysis from a large multicenter cohort incorporating 14,433 HIV-1–infected patients 
in Germany. Treatment-naive patients beginning antiretroviral therapy (ART) with CD4+ cell counts 
<200 cells/μL who achieved complete and sustained viral suppression <50 copies/mL (n = 1318) were 
stratified according to the duration of immuno-virological discordance (failure to achieve a CD4+ cell 
count ≥200 cells/μL). Groups were compared by descriptive and Poisson statistics. The time-varying 
discordance status was analyzed in a multivariable Cox model.  
Results. During a total of 5038 person years of follow-up, 42 new AIDS events occurred. The 
incidence rate of new AIDS events was highest in the initial 6 months of complete viral suppression 
(immuno-virological discordance group, 55.06; 95% confidence interval [CI], 30.82–90.82; and 
immune responder group, 24.54; 95% CI, 10.59–48.35) and decreased significantly by 65% per year 
in patients with immuno-virological discordance (incidence risk ratio, 0.35; 95% CI, 0.14–0.92; P = 
.03). Immuno-virological discordance and prior AIDS diagnosis were independently associated with 
new AIDS events (hazard ratio, 3.10; 95% CI, 1.09–8.82; P = .03).  
Conclusion. Compared with immune responders, patients with immuno-virological discordance 
seem to remain at increased risk for AIDS. Absolute risk is greatly reduced after the first 6 months of 
complete viral suppression.  
 
Antiretroviral therapy (ART) has led to a dramatic reduction in AIDS related morbidity and mortality 
among human immunodeficiency virus (HIV)–infected patients [1–3]. The risk to develop AIDS clearly 
depends on immune reconstitution and viral suppression during therapy, and prognosis is best for 
patients who show both recovery of CD4+ cell counts and sustained viral suppression [4, 5]. Currently, 
up to 30% of patients still present late to HIV centers in Europe in advanced stages of 
immunodeficiency (CD4+ cell counts of <200 cells/μL) and are therefore at high risk to develop AIDS 
[6–10]. Results from observational studies suggest that at least 73.5% of patients initiating ART 
achieve complete virological suppression within 6 months [11], but 9%–45% of patients do not 
experience an appropriate increase in their CD4+ cell counts in the short term [12, 13]. This condition, 
commonly referred to as immuno-virological discordance, is associated with the CD4+ cell count nadir 
before initiation of ART, and the risk of progression to AIDS and death may be increased in this patient 
population [14–16].  
However, detailed risk progression analyses are largely missing in patients with persisting immuno-
virological discordance. Clinical observation suggests that the rate of new AIDS-defining events may 
be low in this subgroup of patients irrespective of CD4+ cell response. In contrast, some experts 
suggest to change ART regimen or to add immunomodifiers (eg, interleukin-2 or CCR5 antagonists) to 
  
ART regimens for those patients with immuno-virological discordance to augment CD4+ cell count 
increases and to prevent disease progression. In the present study, we evaluated patient 
characteristics associated with immuno-virological discordance and subsequently analyzed the risk of 
developing new AIDS-related events in patients with advanced stages of immunodeficiency who were 




Data were extracted and analyzed from the German ClinSurv cohort (Clinical Surveillance of HIV 
Disease), which is an ongoing observational cohort study incorporating HIV-infected patients from 11 
urban centers in Germany. All consecutive HIV-infected patients seen since 1 January 1999 are 
enrolled. Patients have routine follow-up visits every 3 months according to national guidelines. At the 
end of June 2008, 14,433 patients were included in this study. All available clinical data, as well as 
virological and immunological parameters and details of anti-viral therapy, are recorded in local 
electronic databases and transmitted biannually to the coordinating Robert Koch Institute, which is 
also responsible for monitoring and source data verification. The ClinSurv study has been approved by 
the German Federal Commissioner for Data Protection and Freedom of Information.  
 
Data Analysis 
All patients in the cohort who were treatment naive and had a CD4+ cell count of <200 cells/μL before 
commencing highly active ART were included in this analysis. In addition, patients were required to 
achieve a nondetectable viral load (<50 copies/mL) within 180 days after initiation of ART. Patients 
were followed-up from the first day of complete viral suppression (defined as a viral load <50 
copies/mL; baseline) until either virologic failure (2 consecutive viral load measurements >50 
copies/mL within 180 days or 1 viral load measurement >1000 copies/mL), a new AIDS-defining event, 
or 30 June 2008, whichever occurred first. ART was defined as the combination of at least 3 
antiretroviral drugs (a regimen containing either a protease inhibitor [PI] or nonnucleoside reverse-
transcriptase inhibitor [NNRTI] or a triple–nucleoside reverse-transcriptase inhibitor [NRTI] regimen).  
 
Immune Response and Discordance 
By definition, all patients included in the study had CD4+ cell counts of <200 cells/μL at or before 
initiation of ART. Immune response was defined as a documented CD4+ cell count increase to >200 
cells/μL on at least one occasion, even if the CD4+ cell count decreased again to <200 cells/μL during 
subsequent follow-up. Immuno-virological discordance was defined as the failure to surpass the 
threshold of 200 CD4+ cells/μL. Patients were uniquely grouped according to duration of immuno-
virological discordance (0–6, 7–12, 13–24, or >24 months of complete viral suppression). If, for 
example, a patient had an immune response with an increase in CD4+ cell count to >200 cells/μL at 
month 14 of complete viral suppression, then this patient was regarded as having immuno-virological 
discordance for at least 12 months but <24 months (group C in Table 1).  
 
AIDS-Defining Events 
AIDS-defining events were defined according to the European AIDS surveillance case definition [17]. 
Cases fulfilling the criteria for AIDS were followed up by the principal investigator and validated after 
critical chart review with the primary treating physician in each case individually. Presumptive 
diagnoses that proved to be incorrect or unconfirmed diagnoses were excluded from the analysis. 
Opportunistic infection prophylaxis was administered according to national guidelines.  
Statistics 
Variables tested both in descriptive and time-dependent multivariable models included possible 
confounders and effect modifiers, such as age, sex, transmission risk group, ethnic origin, nadir CD4+ 
cell count before initiation of ART, prior AIDS-defining event, year of initiation of ART (before vs after 1 
January 2001, when contemporary boosted PI–containing ART became available in Germany). 
Transmission risk was documented on the basis of the most likely mode of HIV transmission. 
Characteristics of patients with immune response and immuno-virological discordance were compared 
  
using parametric and nonparametric tests, including the χ
2
 test, the Student’s t test, analysis of 
variance, and the rank-sum test.  
Incidence rates were calculated for every 6 month period in the first year and for the second, third, and 
fourth year and were normalized per 1000 person years. A Poisson model was fitted to calculate the 
incidence rate ratios (IRRs) for new AIDS events per year of complete viral suppression in immune 
responders and patients with immuno-virological discordance.  
The Cox proportional hazards model included all of static variables mentioned above. In addition, the 
time-updated immuno-virological discordance (always defined by a CD4+ cell count <200 cells/μL), as 
well as immune response status in 2 steps (defined by CD4+ cell counts of 200–350 cells/μL and >350 
cells/μL), were introduced into the model. The highest ever achieved immune response status was 
carried forward. Proportional hazards assumptions were confirmed using Schoenfeld's test.  
All analyses were performed in Stata software, version 10 (Stata). A P value of <.05 was considered to 
be statistically significant, and all tests of significance were 2-sided.  
 
Results 
Among a total of 14,433 patients in the entire cohort, 11,098 patients were receiving ART as of 30 
June 2008. Of these individuals, 1318 (11.9%) were ART naive, started ART at a CD4+ cell count of 
<200 cells/μL, and achieved a viral load <50 copies/mL within 180 days after initiation of therapy and 
were thus eligible for this analysis. Among these patients, 96 new AIDS diagnoses were documented, 
of which 49 proved to be incorrect or could not be confirmed on data verification and which were thus 
excluded from the analysis. In addition, 5 AIDS-defining events occurred on the first day of viral 
suppression (baseline) and were also excluded. Reasons for incorrect diagnoses included: (1) 
diagnosis occurred in the past and was no longer valid; (2) diagnosis was presumptive and based on 
clinical assumptions only and was not confirmed by laboratory, serologic, or radiologic tests; (3) 
diagnosis was based on serologic test results only, without a clinical correlate. The remaining 
confirmed AIDS-defining events (n = 42) were included in the analysis. Excluded patients were more 
likely to originate from Germany (P = .01) but did not differ from included patients in terms of age, sex, 
transmission risk, prior AIDS-defining event, or nadir CD4+ cell count before initiation of ART (P > .33 
for all).  
In total, 5038 person-years of follow-up with full suppression of viral load to levels <50 HIV RNA 
copies/mL were available for this analysis. A total of 129 patients (9.8%) had ≥1 or more viral blips, 
defined as a viral load >50 copies/mL and <1000 copies/mL followed by a viral load <50 copies/mL.  
 
Patient Characteristics 
Median patient age was 39 years (interquartile range [IQR], 33–47 years), and 77.0% of the patients 
were male. Men having sex with men was the most frequent mode of transmission (45.7%); 69.9% of 
patients originated from Germany, and 12.6% originated from sub-Sahara Africa.  
A total of 599 patients (43.0%) already had an AIDS-defining diagnosis at or before initiation of ART. 
Nadir CD4+ cell count before initiation of ART was 80 cells/μL (IQR, 30–150 cells/μL). Viral 
suppression to levels below 50 copies/mL was achieved after a mean (± standard deviation [SD]) 
duration of 100.1 ± 42.3 days after ART was commenced.  
 
Differences between Early Responders and Patients with Long-term Immuno-Virological 
Discordance 
Compared with patients with immune response in the first 6 months of viral suppression (group A in 
Table 1), patients with long-term immuno-virological discordance for at least 24 months (group D in 
Table 1) were older (median age, 42 years [IQR, 36–52 years] vs 38 years [IQR, 33–46 years]; P = 
.03) and were more likely to have experienced an AIDS-defining event at or before initiation of ART 
(65.4% vs 37.2%; P < .001). Nadir CD4+ cell count before initiation of ART was lower (median CD4+ 
cell count, 21 cells/μL [IQR, 10–47 cells/μL] vs 123 cells/μL [IQR, 62–170 cells/μL]; P < .001) and 
  
mean time to viral load suppression (HIV RNA level <50 copies/mL) was significantly shorter (84 days 
[IQR, 60–116 days] vs 106 days [IQR, 72–138 days]; P = .004). Time from baseline (first day of 
complete viral suppression) to new AIDS-defining event was shorter in patients with early response 
(median duration, 298 days [IQR, 99–493 days] vs 701.5 days [IQR, 701–702 days]; P = .002). Patient 
characteristics according to duration of immuno-virological discordance can be seen in Table 1.  
 
AIDS-Defining Events 
A total of 42 new AIDS-defining events occurred. Incidence for new AIDS-defining events was highest 
in the first year of full viral suppression in both groups. Within the first year, incidence rates were more 
than twice as high in the first 6 months (20.6 [95% CI, 8.9–40.7] in the immune response group and 
55.1 [95% CI, 30.8–90.8] in the immuno-virological discordance group), compared with months 7–12 
(8.0 [95% CI, 1.6–23.2] in the immune response group and 22.1 [95% CI, 4.6–64.5] in the immuno-
virological discordance group; Table 2). Incidence rates decreased by 65% per year of complete viral 
suppression in patients with immuno-virological discordance (IRR, .35; 95% CI, 0.14–0.92; P = .03) 
and by 41% per year in patients with immune response (IRR, 0.59; 95% CI, 0.39–0.90; P = .01). The 
decrease in incidence rates in patients with immuno-virological discordance is depicted in Figure 1.  
Mycobacterial disease (tuberculosis and atypical mycobacterial infections) was the most frequent 
diagnosis and occurred early, at a median of 28 days (IQR, 26–44 days; total of 5 events) in patients 
with immuno-virological discordance and at a median of 711 days (IQR, 605–834 days; total of 2 
events) in patients with immune response. Esophageal candidiasis (total of 6 events) and Kaposi 
sarcoma (total of 5 events) were among other commonly documented AIDS-defining events.  
Overall, 6 (14.3%) of 42 patients had recurrence of a prior AIDS diagnosis (1 case each of recurrent 
cerebral toxoplasmosis, Kaposi sarcoma, chronic herpetic ulcer, and cryptococcal meningitis, and 2 
cases of esophageal candidiasis). Differences in the frequencies of recurrent disease in either group 
were not noted (P = .22). The occurrence of AIDS-defining events is shown in Figure 2. More than 
one-half (54.8%) of all documented diagnoses occurred early in the first 6 months of viral suppression, 
and an additional 14.3% occurred in months 6–12.  
After 2 years, no additional AIDS-defining events occurred among patients with immuno-virological 
discordance. (Figure 2). In patients with immune response, 1 case of recurrent cryptococcal meningitis 
occurred at month 36, 1 case of recurrent herpetic ulcer occurred at month 36, and 1 case of recurrent 
esophageal candidiasis occurred at month 73 of complete viral suppression.  
 
Cox Proportional Hazards Model 
In the Cox proportional hazards model that incorporated all available follow-up data up to 3 years of 
complete viral suppression, receipt of an AIDS diagnosis prior to commencing ART (hazard ratio [HR], 
2.58; 95% CI, 1.24–5.38; P = .01) and immuno-virological discordance (HR, 3.10; 95% CI, 1.09–8.82; 
P = .03, time updated) were independently associated with new AIDS-defining events (Table 3).  
 
Discussion 
In this analysis from a large observational cohort, we included treatment-naive HIV-infected patients 
who started ART with CD4+ cell counts <200 cells/μL. Risk of new AIDS events was assessed in 
patients who achieved a complete and sustained virological response (HIV RNA <50 copies/mL during 
the entire time of observation). The principal findings of this study suggest that most new AIDS events 
(54.8%) occur in the first 6 months after achieving complete viral suppression during ART. Incidence 
rates for new AIDS-defining events dramatically decreased by 65% per year in patients with immuno-
virological discordance, as well as in patients with immune response (41% per year of complete viral 
suppression). Immuno-virological discordance (HR, 3.10; 95% CI, 1.09–8.82; P = .03) and receipt of 
an AIDS diagnosis prior to commencing ART (HR, 2.58; 95% CI, 1.24–5.38; P = .01) remain risk 
factors for new AIDS-defining events in the multivariable Cox analysis. However, absolute risk for 
AIDS is clearly reduced in the mid- to long-term, even among patients with immuno-virological 
discordance. No additional AIDS diagnoses were observed after year 2 of complete virological 
suppression with a minimum residual occurrence of events in immune responders.  
  
Overall, the incidence rate of new AIDS-defining events in the whole cohort was surprisingly low. Only 
42 new AIDS-defining events occurred in >5000 person-years of follow-up, underlining the clinical 
benefit of achieving an undetectable viral load during ART, irrespective of the individual CD4+ cell 
count. Moreover, in patients with immuno-virological discordance, 75% of AIDS-defining events 
occurred within the first 6 months after achieving sustained virological response. Mycobacterial 
diseases were detected frequently in this group, which may be interpreted as the occurrence of 
immune reconstitution inflammatory syndrome.  
These data represent important and previously unreported aspects influencing clinical care of patients 
with HIV infection. Although normalization of CD4+ cell counts is potentially achievable in the long 
term [18], a number of patients do not achieve immune reconstitution despite the absence of active 
viral replication [19]. Current guidelines assume a constantly elevated AIDS risk and recommend 
prophylaxis for several opportunistic infections as long as CD4+ cell counts remain <200 cells/μL, 
which may contribute to additional toxicity, drug interactions, and costs [20]. So far, strategies to boost 
CD4+ cell counts in the light of antiretroviral treatment by co-administration of interleukin 2 have failed 
to show a clinical benefit [21]. Certain antiretroviral compounds (eg, zidovudine and didanosine) may 
impair CD4+ cell recovery [22], and boosted PI– or maraviroc-containing regimens may lead to more 
pronounced CD4+ cell gains [23, 24], compared with NNRTI-based combinations, but this has not 
been proven to translate into clinical benefits as long as viral suppression is achieved [25]. Thus, 
switching a virologically successful regimen just to increase the peripheral CD4+ cell count may not be 
beneficial or justified on the basis of current evidence. Unfortunately, we could not analyze the 
contribution of different antiviral compounds (eg, zidovudine, stavudine, and didanosine) on immuno-
virological discordance from our database.  
Results from the SMART study suggest that the latest CD4+ cell count can only predict opportunistic 
disease in patients who are not receiving therapy [26]. In concert with these data, our results indicate 
that CD4+ cell counts are of limited use as long-term surrogates for absolute AIDS risk as long as 
complete virological suppression is sustained. Moreover, current risk assessments according to CD4+ 
cell count status and recommendations for the prophylaxis of opportunistic disease are derived from 
studies before the ART era or in populations with uncontrolled viral replication. Overall the quality of 
immunological recovery seems to be better reflected by continuous control of viremia rather than by 
the absolute CD4+ cell count increase alone. This may be best explained by a restoration of functional 
immune responses against opportunistic microbes once the prevailing HIV antigens are absent during 
ART, rather than just increasing absolute peripheral T cell numbers. This notion is further supported by 
the fact that we did not observe any significant difference (P = .30) in clinical progression in patients 
who had a CD4+ cell count increase to >350 cells/μL, compared with the group that achieved CD4+ 
cell counts of 200–350/μL during therapy (Table 3).  
Our analysis is limited by several factors. First, our results can only be applied to treatment-naive 
patient populations with advanced immune deficiency (CD4+ cell counts <200 cells/μL) at initiation of 
ART who achieve complete and sustained viral suppression. Second, we cannot exclude that not all 
opportunistic infection prophylaxis was always taken as recommended by local guidelines. Even 
though very few opportunistic diseases that are preventable by opportunistic infection prophylaxis 
occurred in patients with immuno-virological discordance, we cannot exclude that this observation is 
attributed to a higher use of prophylactic medication. Thus, our data do not support discontinuation of 
opportunistic infection prophylaxis in this group in general. However, in a previous study, the 
discontinuation of Pneumocystis carinii pneumonia prophylaxis with trimethoprim-sulfamethoxazole 
was found to be feasible even in patients with a CD4+ cell count <200 cells/μL if viral replication was 
sufficiently suppressed [27].  
Third, the majority of our patients had rapid immune responses, with CD4+ cell counts >200 cells/μL in 
the first 6 months of viral suppression, and only 17 patients had long-term immuno-virological 
discordance beyond 2 years. For patients with long-term immuno-virological discordance, incidence 
rates for AIDS events are affected by large confidence intervals. However, these patients contributed 
13% of total follow-up data for immuno-virological discordance, and reassuringly, not a single AIDS 
event was documented. Analysis of long-term immuno-virological discordance in even larger cohort 
collaborations could provide additional information here. Finally, we could not address the question of 
whether patients with immuno-virological discordance are at higher risk to develop non–AIDS-defining 
diseases, because these were not documented in the database from the beginning of the analysis.  
  
In conclusion, these data from a large multicenter cohort show that the risk to develop new AIDS-
defining events is substantially reduced after the first 6 months of complete viral suppression, 
irrespective of the numeric indicators of immune reconstitution. In patients with immuno-virological 
discordance, incidence rates decreased by 65% per year of complete viral suppression. Although the 
relative risk to develop AIDS may be higher for these patients, compared with the risk for patients with 
immune response, the limited reduction of absolute risk in the mid- to long-term does not support 
strategies to boost CD4+ cell counts, such as switching an NNRTI to a boosted PI or adding CCR5 
antagonists or other immunomodifiers (eg, interleukin 2). This should further encourage physicians to 
define complete viral suppression as the primary goal for their patients who are receiving ART, 
including those patients who start therapy in advanced stages of immune deficiency.  
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Tables and Figures 
 
 




NOTE. Patients are uniquely stratified to whether immune response (defined as CD4+ cell count ≥200 
cells/μL) is achieved within 6 months of complete viral suppression (group A) or immune-virological 
discordance (failure to achieve a CD4+ cell count ≥200 cells/μL) is present for at least 6 but <12 
months (group B), at least 12 but <24 months (group C), or for at least 24 months (group D). Baseline 
is defined as the first viral load <50 copies/mL. ART, antiretroviral therapy; IQR, interquartile range.  
a
 Compared using χ
2
 statistics.  
b
 Compared using nonparametric test for equality of the median.  
 
 
Table 2.  Incidence Rates of New AIDS-defining Events in Patients with Immune Response (CD4+ 
Cell Count ≥200 cells/μL) and Immuno-virological Discordance (Failure to Achieve CD4+ Cell Count 
≥200 cells/μL)  
 
NOTE. ART, antiretroviral therapy; CI, confidence interval; IR, incidence rate; PYFU, person-year of 
follow-up.  
a
 In patients with immune response, 1 AIDS-defining event (recurrent esophageal candidiasis) 
occurred at month 73.  
 
  
Table 3. Cox Proportional Hazards Model Analyzing Risk Factors for New AIDS-defining Events in 





NOTE. CI, confidence interval.  
a
 Reference group is all other patients.  
b







































Figure 1. Incidence of new AIDS-defining events in patients with immuno-virological discordance and 
complete and sustained viral suppression. X represents the observed incidence for new AIDS-defining 
events for months 0–6, months 6–12, years 1–2, years 2–3, and years 3–4; the continuous line 
represents the output of a Poisson Model estimating the incidence trend with 95% confidence intervals 








Figure 2.  Occurrence of AIDS-defining events according to immune response and immuno-virological 
discordance. Among the immune responder group, 1 AIDS-defining event (recurrent esophageal 
candidiasis) occurred at month 73. Abbreviations: TB/MAI, tuberculosis/mycobacterium avium 
intracellulare; PML, progressive multifocal leucencephalopathy; PCP, pneumocystis pneumonia; HSV, 
herpes simplex virus infection;Cervical CA, cancer of the cervix; CMV, cytomegalovirus endorgan 
disease.  
 
 
 
